Homer J J, Greenman J, Stafford N D
Department of Otolaryngology-Head and Neck Surgery, Hull Royal Infirmary, University of Hull, Hull, UK.
Clin Otolaryngol Allied Sci. 2002 Feb;27(1):32-7. doi: 10.1046/j.0307-7772.2001.00519.x.
This pilot study investigated the potential use of three circulating angiogenesis-related cytokines, basic fibroblast growth factor (bFGF), angiogenin (ANG) and endostatin, as tumour markers and prognostic factors in patients with head and neck squamous cell carcinoma (HNSCC). A total of 30 patients with HNSCC treated with curative intent and 15 healthy controls were studied. Serum (bFGF and ANG) and plasma (endostatin) was assayed by enzyme-linked immunoabsorbance assay (ELISA). None of the cytokines was raised in HNSCC patients when compared with controls. Serum bFGF was not associated with any clinico-pathological or outcome parameters, although there was a trend towards higher levels in more advanced and aggressive tumours. Lower serum angiogenin (sANG) levels were associated with loco-regional disease recurrence (P = 0.036). Using a cut-off level of 400 pg/mL, a low level of sANG predicted tumour recurrence with a relative risk of 4.0 (95% CI: 0.7-24.0). Plasma endostatin was associated with higher histological grade (P = 0.01) and with both disease recurrence (P = 0.045) and death from disease (P = 0.021). Plasma endostatin above a cut-off point of 70 ng/mL could predict tumour recurrence with a relative risk of 4.7 (95% CI: 1.1-19.7). These data suggest that plasma endostatin and sANG have potential roles as prognostic factors and require further investigation.
这项初步研究调查了三种循环血管生成相关细胞因子，即碱性成纤维细胞生长因子（bFGF）、血管生成素（ANG）和内皮抑素，作为头颈部鳞状细胞癌（HNSCC）患者肿瘤标志物和预后因素的潜在用途。共研究了30例接受根治性治疗的HNSCC患者和15名健康对照者。采用酶联免疫吸附测定（ELISA）法检测血清（bFGF和ANG）和血浆（内皮抑素）。与对照组相比，HNSCC患者中这些细胞因子均未升高。血清bFGF与任何临床病理或预后参数均无关联，尽管在更晚期和侵袭性更强的肿瘤中存在水平升高的趋势。较低的血清血管生成素（sANG）水平与局部区域疾病复发相关（P = 0.036）。使用400 pg/mL的临界值，低水平的sANG预测肿瘤复发的相对风险为4.0（95%可信区间：0.7 - 24.0）。血浆内皮抑素与更高的组织学分级相关（P = 0.01），并与疾病复发（P = 0.045）和疾病死亡（P = 0.021）均相关。血浆内皮抑素高于70 ng/mL的临界点可预测肿瘤复发，相对风险为4.7（95%可信区间：1.1 - 19.7）。这些数据表明，血浆内皮抑素和sANG作为预后因素具有潜在作用，需要进一步研究。
